Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) CEO Markus Warmuth sold 5,466 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $23.49, for a total transaction of $128,396.34. Following the completion of the sale, the chief executive officer owned 618,937 shares of the company’s stock, valued at approximately $14,538,830.13. This represents a 0.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Monte Rosa Therapeutics Stock Down 4.1%

Shares of NASDAQ GLUE traded down $1.03 during midday trading on Friday, reaching $24.28. 5,677,440 shares of the company’s stock traded hands, compared to its average volume of 5,910,646. The company has a market cap of $1.58 billion, a price-to-earnings ratio of 75.88 and a beta of 1.60. The stock’s 50 day simple moving average is $15.78 and its 200-day simple moving average is $9.60. Monte Rosa Therapeutics, Inc. has a one year low of $3.50 and a one year high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.06. The company had revenue of $12.77 million during the quarter, compared to the consensus estimate of $7.37 million. Monte Rosa Therapeutics had a net margin of 11.54% and a return on equity of 8.28%. Equities analysts predict that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Zacks Research upgraded Monte Rosa Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price objective on shares of Monte Rosa Therapeutics in a research report on Wednesday. Jefferies Financial Group reiterated a “buy” rating and set a $31.00 price objective on shares of Monte Rosa Therapeutics in a research note on Wednesday. Cowen restated a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Monte Rosa Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $30.20.

Institutional Investors Weigh In On Monte Rosa Therapeutics

A number of large investors have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at about $271,000. Wealth Enhancement Advisory Services LLC raised its position in Monte Rosa Therapeutics by 20.2% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,289 shares of the company’s stock valued at $357,000 after acquiring an additional 3,746 shares in the last quarter. GAMMA Investing LLC acquired a new position in Monte Rosa Therapeutics in the fourth quarter valued at approximately $30,000. Vestal Point Capital LP purchased a new stake in Monte Rosa Therapeutics in the 3rd quarter worth approximately $5,928,000. Finally, Scientech Research LLC purchased a new stake in Monte Rosa Therapeutics in the 3rd quarter worth approximately $120,000. 79.96% of the stock is owned by hedge funds and other institutional investors.

Key Monte Rosa Therapeutics News

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: Interim Phase I data showed MRT‑8102 produces deep NEK7 degradation and drove a large reduction in inflammation markers, which triggered a big intraday rally in the stock. GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
• Positive Sentiment: Early trial readouts reported ~85% CRP reduction (a key inflammation marker), reinforcing clinical promise for MRT‑8102 and sparking investor enthusiasm. Monte Rosa stock surges after positive data shows 85% CRP reduction
• Positive Sentiment: Analysts reacted to the clinical news with bullish moves — Guggenheim raised its PT to $34 and issued a Buy, and Wells Fargo raised its PT to $30 with an Overweight. These actions support upside from fundamentals if clinical progress continues. Benzinga
• Positive Sentiment: Zacks upgraded GLUE from Hold to Strong Buy amid the data-driven momentum, adding to short‑term buyer interest. Zacks.com upgrade
• Neutral Sentiment: Several market watchers flagged GLUE as a “stock on the move,” highlighting momentum and technical strength that could attract momentum traders. Monte Rosa Therapeutics (GLUE) is on the Move
• Negative Sentiment: Monte Rosa priced an underwritten public offering to raise roughly $300 million: 11,125,000 shares at $24.00 plus 1,375,000 pre‑funded warrants at $23.9999. The timing — immediately after a sharp rally — increases share supply and dilution risk, which likely weighed on the stock. Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.